^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Factor VIII stimulant

    Associations

    News

    Trials
    19h
    Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A (clinicaltrials.gov)
    P1, N=24, Recruiting, Swedish Orphan Biovitrum | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    1m
    A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A (clinicaltrials.gov)
    P2, N=5, Not yet recruiting, Hoffmann-La Roche
    New P2 trial
    2ms
    Safety, Efficacy, and Pharmacokinetic Evaluation of rVWF in Chinese Subjects With von Willebrand Disease (ChiCTR2500108310)
    P3, N=20, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P3 trial
    2ms
    SYNOVIIIUS: Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy (clinicaltrials.gov)
    P4, N=35, Recruiting, Sanofi | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Oct 2027 | Initiation date: May 2025 --> Sep 2025 | Trial primary completion date: Mar 2027 --> Oct 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    2ms
    Drug Use Investigation of Kovaltry in Hemophilia A Patients (clinicaltrials.gov)
    P=N/A, N=230, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    2ms
    GENEr8-3: Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (clinicaltrials.gov)
    P3, N=22, Completed, BioMarin Pharmaceutical | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> May 2025
    Trial completion • Trial completion date
    3ms
    PROTECT-ALT: A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Sanofi | Initiation date: Jan 2024 --> Nov 2024
    Trial initiation date
    3ms
    A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A (clinicaltrials.gov)
    P=N/A, N=200, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | Trial completion date: Jun 2028 --> Sep 2030
    Enrollment closed • Trial completion date
    3ms
    FRONTIER4: A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) (clinicaltrials.gov)
    P3, N=451, Active, not recruiting, Novo Nordisk A/S | Trial completion date: Dec 2030 --> Jun 2028 | Trial primary completion date: Dec 2030 --> Jun 2028
    Trial completion date • Trial primary completion date
    3ms
    Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Novo Nordisk A/S | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    3ms
    Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol (clinicaltrials.gov)
    P=N/A, N=50, Enrolling by invitation, Novo Nordisk A/S | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Adverse events
    3ms
    LIBERTY: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa (clinicaltrials.gov)
    P3, N=104, Recruiting, Swedish Orphan Biovitrum | N=78 --> 104 | Trial completion date: Aug 2026 --> Mar 2027 | Trial primary completion date: Aug 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date